Kirin Holdings Co. (OTCMKTS:KNBWY) Short Interest Down 62.7% in August
by Teresa Graham · The Cerbat GemKirin Holdings Co. (OTCMKTS:KNBWY – Get Free Report) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 28,981 shares, a drop of 62.7% from the August 15th total of 77,766 shares. Based on an average daily volume of 25,911 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.0% of the shares of the company are sold short.
Kirin Price Performance
Shares of KNBWY opened at $18.33 on Tuesday. The firm has a 50 day simple moving average of $18.55 and a two-hundred day simple moving average of $17.26. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.44 and a quick ratio of 1.01. Kirin has a one year low of $14.01 and a one year high of $19.99. The company has a market cap of $14.85 billion, a P/E ratio of 11.67 and a beta of -0.01.
Kirin (OTCMKTS:KNBWY – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.16. Kirin had a return on equity of 12.29% and a net margin of 7.79%.The company had revenue of $4.08 billion for the quarter, compared to analyst estimates of $3.87 billion. Research analysts forecast that Kirin will post 1.34 EPS for the current fiscal year.
Analysts Set New Price Targets
Separately, Zacks Research cut Kirin from a “hold” rating to a “strong sell” rating in a research note on Monday, August 31st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.
Get Our Latest Stock Report on Kirin
Kirin Company Profile
Kirin Holdings Company, Limited is a Japan-based company with businesses spanning alcoholic and nonalcoholic beverages, pharmaceuticals and health science. Its beverage operations include beer, wine, spirits, soft drinks, bottled water and other consumer products marketed under brands such as Kirin, Ichiban Shibori and Afternoon Tea.
The company’s pharmaceutical business is conducted primarily through Kyowa Kirin, which researches, develops and commercializes prescription medicines, including treatments in areas such as oncology, immunology and nephrology.